C
Charles River Laboratories International, Inc.
CRL
$233.47
$3.581.56%
C
Hold
1/24/2024Upgraded
Charles River Laboratories International, Inc. (CRL) was upgraded to C from C- on 1/24/2024 due to an increase in the valuation index, volatility index and total return index.
Charles River Laboratories International, Inc. (CRL) was upgraded to C from C- on 1/24/2024 due to an increase in the valuation index, volatility index and total return index.
C
Hold
1/9/2024Downgrade
Charles River Laboratories International, Inc. (CRL) was downgraded to C- from C on 1/9/2024 due to a decline in the volatility index and valuation index.
Charles River Laboratories International, Inc. (CRL) was downgraded to C- from C on 1/9/2024 due to a decline in the volatility index and valuation index.
C
Hold
12/22/2023Upgraded
Charles River Laboratories International, Inc. (CRL) was upgraded to C from C- on 12/22/2023 due to an increase in the volatility index and solvency index. Debt to equity declined from 0.82 to 0.75.
Charles River Laboratories International, Inc. (CRL) was upgraded to C from C- on 12/22/2023 due to an increase in the volatility index and solvency index. Debt to equity declined from 0.82 to 0.75.
C
Hold
10/5/2023Downgrade
Charles River Laboratories International, Inc. (CRL) was downgraded to C- from C on 10/5/2023 due to a decline in the total return index and volatility index.
Charles River Laboratories International, Inc. (CRL) was downgraded to C- from C on 10/5/2023 due to a decline in the total return index and volatility index.
C
Hold
8/10/2023Upgraded
Charles River Laboratories International, Inc. (CRL) was upgraded to C from C- on 8/10/2023 due to a large increase in the growth index, volatility index and total return index. Operating cash flow increased 35.42% from $109.38M to $148.12M, and total revenue increased 2.97% from $1.03B to $1.06B.
Charles River Laboratories International, Inc. (CRL) was upgraded to C from C- on 8/10/2023 due to a large increase in the growth index, volatility index and total return index. Operating cash flow increased 35.42% from $109.38M to $148.12M, and total revenue increased 2.97% from $1.03B to $1.06B.
C
Hold
8/7/2023Downgrade
Charles River Laboratories International, Inc. (CRL) was downgraded to C- from C on 8/7/2023 due to a significant decline in the growth index, total return index and volatility index. Operating cash flow declined 53.41% from $234.76M to $109.38M, earnings per share declined from $3.6464 to $2.01, and total revenue declined 6.41% from $1.1B to $1.03B.
Charles River Laboratories International, Inc. (CRL) was downgraded to C- from C on 8/7/2023 due to a significant decline in the growth index, total return index and volatility index. Operating cash flow declined 53.41% from $234.76M to $109.38M, earnings per share declined from $3.6464 to $2.01, and total revenue declined 6.41% from $1.1B to $1.03B.
C
Hold
9/30/2022Downgrade
Charles River Laboratories International, Inc. (CRL) was downgraded to C from C+ on 9/30/2022 due to a decline in the total return index, solvency index and volatility index. Debt to equity increased from 1.03 to 1.14, and the quick ratio declined from 0.96 to 0.91.
Charles River Laboratories International, Inc. (CRL) was downgraded to C from C+ on 9/30/2022 due to a decline in the total return index, solvency index and volatility index. Debt to equity increased from 1.03 to 1.14, and the quick ratio declined from 0.96 to 0.91.
C
Hold
7/21/2022Upgraded
Charles River Laboratories International, Inc. (CRL) was upgraded to C+ from C on 7/21/2022 due to an increase in the volatility index, total return index and valuation index.
Charles River Laboratories International, Inc. (CRL) was upgraded to C+ from C on 7/21/2022 due to an increase in the volatility index, total return index and valuation index.
C
Hold
5/26/2022Downgrade
Charles River Laboratories International, Inc. (CRL) was downgraded to C from C+ on 5/26/2022 due to a large decline in the growth index, total return index and volatility index. Operating cash flow declined 55.23% from $229.26M to $102.63M, earnings per share declined from $2.6695 to $1.81, and EBIT declined 14.45% from $182.2M to $155.88M.
Charles River Laboratories International, Inc. (CRL) was downgraded to C from C+ on 5/26/2022 due to a large decline in the growth index, total return index and volatility index. Operating cash flow declined 55.23% from $229.26M to $102.63M, earnings per share declined from $2.6695 to $1.81, and EBIT declined 14.45% from $182.2M to $155.88M.
C
Hold
3/7/2022Downgrade
Charles River Laboratories International, Inc. (CRL) was downgraded to C+ from B- on 3/7/2022 due to a large decline in the volatility index and total return index.
Charles River Laboratories International, Inc. (CRL) was downgraded to C+ from B- on 3/7/2022 due to a large decline in the volatility index and total return index.
B
Buy
12/8/2021Downgrade
Charles River Laboratories International, Inc. (CRL) was downgraded to B- from B on 12/8/2021 due to a significant decline in the total return index, growth index and volatility index. Operating cash flow declined 6.36% from $186.59M to $174.72M, and total revenue declined 2.04% from $914.61M to $895.94M.
Charles River Laboratories International, Inc. (CRL) was downgraded to B- from B on 12/8/2021 due to a significant decline in the total return index, growth index and volatility index. Operating cash flow declined 6.36% from $186.59M to $174.72M, and total revenue declined 2.04% from $914.61M to $895.94M.
B
Buy
11/3/2021Downgrade
Charles River Laboratories International, Inc. (CRL) was downgraded to B from B+ on 11/3/2021 due to a decline in the total return index, volatility index and valuation index.
Charles River Laboratories International, Inc. (CRL) was downgraded to B from B+ on 11/3/2021 due to a decline in the total return index, volatility index and valuation index.
B
Buy
10/8/2021Upgraded
Charles River Laboratories International, Inc. (CRL) was upgraded to B+ from B on 10/8/2021 due to a substantial increase in the total return index, growth index and volatility index. Earnings per share increased from $1.2 to $1.72, EBIT increased 17.09% from $132.11M to $154.69M, and total revenue increased 10.92% from $824.57M to $914.61M.
Charles River Laboratories International, Inc. (CRL) was upgraded to B+ from B on 10/8/2021 due to a substantial increase in the total return index, growth index and volatility index. Earnings per share increased from $1.2 to $1.72, EBIT increased 17.09% from $132.11M to $154.69M, and total revenue increased 10.92% from $824.57M to $914.61M.
B
Buy
8/7/2020Upgraded
Charles River Laboratories International, Inc. (CRL) was upgraded to B from B- on 8/7/2020 due to a noticeable increase in the growth index, valuation index and total return index. Operating cash flow increased 136.63% from $68.59M to $162.31M, and earnings per share increased from $1.02 to $1.34.
Charles River Laboratories International, Inc. (CRL) was upgraded to B from B- on 8/7/2020 due to a noticeable increase in the growth index, valuation index and total return index. Operating cash flow increased 136.63% from $68.59M to $162.31M, and earnings per share increased from $1.02 to $1.34.
B
Buy
7/22/2020Downgrade
Charles River Laboratories International, Inc. (CRL) was downgraded to B- from B on 7/22/2020 due to a decline in the valuation index.
Charles River Laboratories International, Inc. (CRL) was downgraded to B- from B on 7/22/2020 due to a decline in the valuation index.
B
Buy
7/7/2020Upgraded
Charles River Laboratories International, Inc. (CRL) was upgraded to B from B- on 7/7/2020 due to a substantial increase in the total return index.
Charles River Laboratories International, Inc. (CRL) was upgraded to B from B- on 7/7/2020 due to a substantial increase in the total return index.
B
Buy
4/23/2020Downgrade
Charles River Laboratories International, Inc. (CRL) was downgraded to B- from B on 4/23/2020 due to a noticeable decline in the volatility index, total return index and growth index.
Charles River Laboratories International, Inc. (CRL) was downgraded to B- from B on 4/23/2020 due to a noticeable decline in the volatility index, total return index and growth index.
B
Buy
12/24/2019Downgrade
Charles River Laboratories International, Inc. (CRL) was downgraded to B from B+ on 12/24/2019 due to a decline in the valuation index.
Charles River Laboratories International, Inc. (CRL) was downgraded to B from B+ on 12/24/2019 due to a decline in the valuation index.
B
Buy
12/3/2019Upgraded
Charles River Laboratories International, Inc. (CRL) was upgraded to B+ from B on 12/3/2019 due to an increase in the growth index, volatility index and total return index. Earnings per share increased from $0.88 to $1.46, operating cash flow increased 20.3% from $129.55M to $155.85M, and EBIT increased 17.2% from $81.23M to $95.21M.
Charles River Laboratories International, Inc. (CRL) was upgraded to B+ from B on 12/3/2019 due to an increase in the growth index, volatility index and total return index. Earnings per share increased from $0.88 to $1.46, operating cash flow increased 20.3% from $129.55M to $155.85M, and EBIT increased 17.2% from $81.23M to $95.21M.
B
Buy
2/15/2019Upgraded
Charles River Laboratories International, Inc. (CRL) was upgraded to B from C+ on 2/15/2019 due to a significant increase in the growth index, valuation index and efficiency index. Operating cash flow increased 19.39% from $117.24M to $139.97M, EBIT increased 14.62% from $90.69M to $103.94M, and total revenue increased 2.77% from $585.3M to $601.53M.
Charles River Laboratories International, Inc. (CRL) was upgraded to B from C+ on 2/15/2019 due to a significant increase in the growth index, valuation index and efficiency index. Operating cash flow increased 19.39% from $117.24M to $139.97M, EBIT increased 14.62% from $90.69M to $103.94M, and total revenue increased 2.77% from $585.3M to $601.53M.
C
Hold
1/8/2019Downgrade
Charles River Laboratories International, Inc. (CRL) was downgraded to C+ from B- on 1/8/2019 due to a large decline in the total return index and volatility index.
Charles River Laboratories International, Inc. (CRL) was downgraded to C+ from B- on 1/8/2019 due to a large decline in the total return index and volatility index.
B
Buy
11/14/2018Upgraded
Charles River Laboratories International, Inc. (CRL) was upgraded to B- from C+ on 11/14/2018 due to a noticeable increase in the growth index, total return index and solvency index. Debt to equity declined from 1.52 to 1.32, earnings per share increased from $1.0912 to $1.22, and EBIT increased 0.05% from $90.65M to $90.69M.
Charles River Laboratories International, Inc. (CRL) was upgraded to B- from C+ on 11/14/2018 due to a noticeable increase in the growth index, total return index and solvency index. Debt to equity declined from 1.52 to 1.32, earnings per share increased from $1.0912 to $1.22, and EBIT increased 0.05% from $90.65M to $90.69M.
C
Hold
11/8/2018Downgrade
Charles River Laboratories International, Inc. (CRL) was downgraded to C+ from B- on 11/8/2018 due to a decline in the total return index and valuation index.
Charles River Laboratories International, Inc. (CRL) was downgraded to C+ from B- on 11/8/2018 due to a decline in the total return index and valuation index.
B
Buy
10/24/2018Upgraded
Charles River Laboratories International, Inc. (CRL) was upgraded to B- from C+ on 10/24/2018 due to an increase in the volatility index, total return index and valuation index.
Charles River Laboratories International, Inc. (CRL) was upgraded to B- from C+ on 10/24/2018 due to an increase in the volatility index, total return index and valuation index.
C
Hold
8/14/2018Downgrade
Charles River Laboratories International, Inc. (CRL) was downgraded to C+ from B- on 8/14/2018 due to a substantial decline in the growth index, valuation index and efficiency index.
Charles River Laboratories International, Inc. (CRL) was downgraded to C+ from B- on 8/14/2018 due to a substantial decline in the growth index, valuation index and efficiency index.
B
Buy
5/15/2018Upgraded
Charles River Laboratories International, Inc. (CRL) was upgraded to B- from C on 5/15/2018 due to a significant increase in the growth index, total return index and valuation index. Earnings per share increased from -$0.6385 to $1.0795, and total revenue increased 3.24% from $478.48M to $493.97M.
Charles River Laboratories International, Inc. (CRL) was upgraded to B- from C on 5/15/2018 due to a significant increase in the growth index, total return index and valuation index. Earnings per share increased from -$0.6385 to $1.0795, and total revenue increased 3.24% from $478.48M to $493.97M.
C
Hold
5/1/2018Downgrade
Charles River Laboratories International, Inc. (CRL) was downgraded to C from C+ on 5/1/2018 due to a decline in the total return index.
Charles River Laboratories International, Inc. (CRL) was downgraded to C from C+ on 5/1/2018 due to a decline in the total return index.
C
Hold
3/12/2018Upgraded
Charles River Laboratories International, Inc. (CRL) was upgraded to C+ from C on 3/12/2018 due to an increase in the total return index and solvency index.
Charles River Laboratories International, Inc. (CRL) was upgraded to C+ from C on 3/12/2018 due to an increase in the total return index and solvency index.
C
Hold
2/20/2018Downgrade
Charles River Laboratories International, Inc. (CRL) was downgraded to C from C+ on 2/20/2018 due to a decline in the valuation index and volatility index.
Charles River Laboratories International, Inc. (CRL) was downgraded to C from C+ on 2/20/2018 due to a decline in the valuation index and volatility index.
C
Hold
2/15/2018Downgrade
Charles River Laboratories International, Inc. (CRL) was downgraded to C+ from B on 2/15/2018 due to a significant decline in the growth index, total return index and valuation index. Earnings per share declined from $1.0892 to -$0.6385.
Charles River Laboratories International, Inc. (CRL) was downgraded to C+ from B on 2/15/2018 due to a significant decline in the growth index, total return index and valuation index. Earnings per share declined from $1.0892 to -$0.6385.
B
Buy
11/20/2017Downgrade
Charles River Laboratories International, Inc. (CRL) was downgraded to B from B+ on 11/20/2017 due to a decline in the total return index and volatility index.
Charles River Laboratories International, Inc. (CRL) was downgraded to B from B+ on 11/20/2017 due to a decline in the total return index and volatility index.
B
Buy
11/13/2017Downgrade
Charles River Laboratories International, Inc. (CRL) was downgraded to B+ from A- on 11/13/2017 due to a noticeable decline in the growth index, volatility index and total return index. Operating cash flow declined 40.89% from $99.8M to $58.99M, EBIT declined 8.44% from $83.3M to $76.27M, and earnings per share declined from $1.1185 to $1.0892.
Charles River Laboratories International, Inc. (CRL) was downgraded to B+ from A- on 11/13/2017 due to a noticeable decline in the growth index, volatility index and total return index. Operating cash flow declined 40.89% from $99.8M to $58.99M, EBIT declined 8.44% from $83.3M to $76.27M, and earnings per share declined from $1.1185 to $1.0892.
A
Buy
10/26/2017Upgraded
Charles River Laboratories International, Inc. (CRL) was upgraded to A- from B+ on 10/26/2017 due to a large increase in the total return index and volatility index.
Charles River Laboratories International, Inc. (CRL) was upgraded to A- from B+ on 10/26/2017 due to a large increase in the total return index and volatility index.
B
Buy
9/5/2017Upgraded
Charles River Laboratories International, Inc. (CRL) was upgraded to B+ from B on 9/5/2017 due to a substantial increase in the total return index, volatility index and solvency index. Debt to equity declined from 1.33 to 1.16.
Charles River Laboratories International, Inc. (CRL) was upgraded to B+ from B on 9/5/2017 due to a substantial increase in the total return index, volatility index and solvency index. Debt to equity declined from 1.33 to 1.16.
B
Buy
2/16/2017Upgraded
Charles River Laboratories International, Inc. (CRL) was upgraded to B from B- on 2/16/2017 due to a substantial increase in the growth index, total return index and efficiency index. Operating cash flow increased 64.79% from $68.95M to $113.63M, EBIT increased 22.76% from $67.1M to $82.37M, and net income increased 18.4% from $37.74M to $44.68M.
Charles River Laboratories International, Inc. (CRL) was upgraded to B from B- on 2/16/2017 due to a substantial increase in the growth index, total return index and efficiency index. Operating cash flow increased 64.79% from $68.95M to $113.63M, EBIT increased 22.76% from $67.1M to $82.37M, and net income increased 18.4% from $37.74M to $44.68M.
B
Buy
11/9/2016Downgrade
Charles River Laboratories International, Inc. (CRL) was downgraded to B- from B on 11/9/2016 due to a large decline in the total return index, growth index and volatility index. Operating cash flow declined 11.24% from $77.69M to $68.95M, and total revenue declined 1.92% from $434.06M to $425.72M.
Charles River Laboratories International, Inc. (CRL) was downgraded to B- from B on 11/9/2016 due to a large decline in the total return index, growth index and volatility index. Operating cash flow declined 11.24% from $77.69M to $68.95M, and total revenue declined 1.92% from $434.06M to $425.72M.
B
Buy
9/6/2016Downgrade
Charles River Laboratories International, Inc. (CRL) was downgraded to B from B+ on 9/6/2016 due to a substantial decline in the total return index and volatility index.
Charles River Laboratories International, Inc. (CRL) was downgraded to B from B+ on 9/6/2016 due to a substantial decline in the total return index and volatility index.
B
Buy
8/22/2016Upgraded
Charles River Laboratories International, Inc. (CRL) was upgraded to B+ from B on 8/22/2016 due to an increase in the total return index, valuation index and volatility index.
Charles River Laboratories International, Inc. (CRL) was upgraded to B+ from B on 8/22/2016 due to an increase in the total return index, valuation index and volatility index.
B
Buy
8/5/2016Downgrade
Charles River Laboratories International, Inc. (CRL) was downgraded to B from B+ on 8/5/2016 due to a decline in the valuation index, solvency index and efficiency index. Debt to equity increased from 1.07 to 1.61, the quick ratio declined from 1.49 to 1.27, and net income declined 5.21% from $37.14M to $35.21M.
Charles River Laboratories International, Inc. (CRL) was downgraded to B from B+ on 8/5/2016 due to a decline in the valuation index, solvency index and efficiency index. Debt to equity increased from 1.07 to 1.61, the quick ratio declined from 1.49 to 1.27, and net income declined 5.21% from $37.14M to $35.21M.
B
Buy
7/26/2016Downgrade
Charles River Laboratories International, Inc. (CRL) was downgraded to B+ from A- on 7/26/2016 due to a noticeable decline in the total return index, volatility index and valuation index.
Charles River Laboratories International, Inc. (CRL) was downgraded to B+ from A- on 7/26/2016 due to a noticeable decline in the total return index, volatility index and valuation index.
A
Buy
7/11/2016Upgraded
Charles River Laboratories International, Inc. (CRL) was upgraded to A- from B+ on 7/11/2016 due to a noticeable increase in the total return index, volatility index and valuation index.
Charles River Laboratories International, Inc. (CRL) was upgraded to A- from B+ on 7/11/2016 due to a noticeable increase in the total return index, volatility index and valuation index.
B
Buy
6/8/2016Upgraded
Charles River Laboratories International, Inc. (CRL) was upgraded to B+ from B on 6/8/2016 due to an increase in the total return index, growth index and volatility index. Earnings per share increased from $0.6667 to $0.7795, total revenue increased 0.29% from $353.85M to $354.87M, and EBIT increased 0.11% from $57.09M to $57.15M.
Charles River Laboratories International, Inc. (CRL) was upgraded to B+ from B on 6/8/2016 due to an increase in the total return index, growth index and volatility index. Earnings per share increased from $0.6667 to $0.7795, total revenue increased 0.29% from $353.85M to $354.87M, and EBIT increased 0.11% from $57.09M to $57.15M.
B
Buy
3/11/2016Downgrade
Charles River Laboratories International, Inc. (CRL) was downgraded to B from A- on 3/11/2016 due to a significant decline in the volatility index, growth index and solvency index. Earnings per share declined from $0.7893 to $0.6667, and EBIT declined 3.95% from $59.44M to $57.09M.
Charles River Laboratories International, Inc. (CRL) was downgraded to B from A- on 3/11/2016 due to a significant decline in the volatility index, growth index and solvency index. Earnings per share declined from $0.7893 to $0.6667, and EBIT declined 3.95% from $59.44M to $57.09M.
A
Buy
2/9/2016Downgrade
Charles River Laboratories International, Inc. (CRL) was downgraded to A- from A on 2/9/2016 due to a decline in the total return index.
Charles River Laboratories International, Inc. (CRL) was downgraded to A- from A on 2/9/2016 due to a decline in the total return index.
A
Buy
1/20/2016Upgraded
Charles River Laboratories International, Inc. (CRL) was upgraded to A from A- on 1/20/2016 due to a noticeable increase in the total return index, volatility index and valuation index.
Charles River Laboratories International, Inc. (CRL) was upgraded to A from A- on 1/20/2016 due to a noticeable increase in the total return index, volatility index and valuation index.
A
Buy
1/11/2016Upgraded
Charles River Laboratories International, Inc. (CRL) was upgraded to A- from B+ on 1/11/2016 due to a large increase in the volatility index and total return index.
Charles River Laboratories International, Inc. (CRL) was upgraded to A- from B+ on 1/11/2016 due to a large increase in the volatility index and total return index.
B
Buy
11/2/2015Upgraded
Charles River Laboratories International, Inc. (CRL) was upgraded to B+ from B on 11/2/2015 due to an increase in the volatility index and valuation index.
Charles River Laboratories International, Inc. (CRL) was upgraded to B+ from B on 11/2/2015 due to an increase in the volatility index and valuation index.
B
Buy
10/1/2015Downgrade
Charles River Laboratories International, Inc. (CRL) was downgraded to B from B+ on 10/1/2015 due to a decline in the volatility index.
Charles River Laboratories International, Inc. (CRL) was downgraded to B from B+ on 10/1/2015 due to a decline in the volatility index.
B
Buy
9/25/2015Downgrade
Charles River Laboratories International, Inc. (CRL) was downgraded to B+ from A- on 9/25/2015 due to a noticeable decline in the volatility index.
Charles River Laboratories International, Inc. (CRL) was downgraded to B+ from A- on 9/25/2015 due to a noticeable decline in the volatility index.
A
Buy
8/28/2015Upgraded
Charles River Laboratories International, Inc. (CRL) was upgraded to A- from B+ on 8/28/2015 due to a noticeable increase in the growth index, valuation index and solvency index. Operating cash flow increased 684.04% from $10.94M to $85.74M, earnings per share increased from $0.6599 to $1.0199, and EBIT increased 28.79% from $43.44M to $55.94M.
Charles River Laboratories International, Inc. (CRL) was upgraded to A- from B+ on 8/28/2015 due to a noticeable increase in the growth index, valuation index and solvency index. Operating cash flow increased 684.04% from $10.94M to $85.74M, earnings per share increased from $0.6599 to $1.0199, and EBIT increased 28.79% from $43.44M to $55.94M.
B
Buy
6/8/2015Downgrade
Charles River Laboratories International, Inc. (CRL) was downgraded to B+ from A- on 6/8/2015 due to a decline in the valuation index and volatility index.
Charles River Laboratories International, Inc. (CRL) was downgraded to B+ from A- on 6/8/2015 due to a decline in the valuation index and volatility index.
A
Buy
5/22/2015Upgraded
Charles River Laboratories International, Inc. (CRL) was upgraded to A- from B+ on 5/22/2015 due to an increase in the solvency index and valuation index.
Charles River Laboratories International, Inc. (CRL) was upgraded to A- from B+ on 5/22/2015 due to an increase in the solvency index and valuation index.
B
Buy
5/7/2015Downgrade
Charles River Laboratories International, Inc. (CRL) was downgraded to B+ from A- on 5/7/2015 due to a noticeable decline in the total return index and solvency index. Debt to equity increased from 1.12 to 1.15.
Charles River Laboratories International, Inc. (CRL) was downgraded to B+ from A- on 5/7/2015 due to a noticeable decline in the total return index and solvency index. Debt to equity increased from 1.12 to 1.15.
A
Buy
2/13/2015Upgraded
Charles River Laboratories International, Inc. (CRL) was upgraded to A- from B+ on 2/13/2015 due to a large increase in the total return index, growth index and volatility index.
Charles River Laboratories International, Inc. (CRL) was upgraded to A- from B+ on 2/13/2015 due to a large increase in the total return index, growth index and volatility index.
B
Buy
11/3/2014Downgrade
Charles River Laboratories International, Inc. (CRL) was downgraded to B+ from A- on 11/3/2014 due to a substantial decline in the growth index and valuation index. EBIT declined 11.43% from $55.49M to $49.15M, earnings per share declined from $0.7365 to $0.6811, and total revenue declined 3.99% from $341.18M to $327.57M.
Charles River Laboratories International, Inc. (CRL) was downgraded to B+ from A- on 11/3/2014 due to a substantial decline in the growth index and valuation index. EBIT declined 11.43% from $55.49M to $49.15M, earnings per share declined from $0.7365 to $0.6811, and total revenue declined 3.99% from $341.18M to $327.57M.
A
Buy
8/8/2014Upgraded
Charles River Laboratories International, Inc. (CRL) was upgraded to A- from B on 8/8/2014 due to a major increase in the growth index, volatility index and valuation index. Operating cash flow increased 104.86% from $27.8M to $56.95M, EBIT increased 30.3% from $42.59M to $55.49M, and total revenue increased 13.97% from $299.37M to $341.18M.
Charles River Laboratories International, Inc. (CRL) was upgraded to A- from B on 8/8/2014 due to a major increase in the growth index, volatility index and valuation index. Operating cash flow increased 104.86% from $27.8M to $56.95M, EBIT increased 30.3% from $42.59M to $55.49M, and total revenue increased 13.97% from $299.37M to $341.18M.
B
Buy
8/1/2014Downgrade
Charles River Laboratories International, Inc. (CRL) was downgraded to B from B+ on 8/1/2014 due to a substantial decline in the volatility index.
Charles River Laboratories International, Inc. (CRL) was downgraded to B from B+ on 8/1/2014 due to a substantial decline in the volatility index.
B
Buy
5/1/2014Upgraded
Charles River Laboratories International, Inc. (CRL) was upgraded to B+ from B on 5/1/2014 due to an increase in the growth index, valuation index and solvency index. Earnings per share increased from $0.3952 to $0.66, EBIT increased 52.95% from $25.96M to $39.71M, and the quick ratio increased from 1.57 to 1.76.
Charles River Laboratories International, Inc. (CRL) was upgraded to B+ from B on 5/1/2014 due to an increase in the growth index, valuation index and solvency index. Earnings per share increased from $0.3952 to $0.66, EBIT increased 52.95% from $25.96M to $39.71M, and the quick ratio increased from 1.57 to 1.76.
B
Buy
4/22/2014Downgrade
Charles River Laboratories International, Inc. (CRL) was downgraded to B from B+ on 4/22/2014 due to a noticeable decline in the total return index.
Charles River Laboratories International, Inc. (CRL) was downgraded to B from B+ on 4/22/2014 due to a noticeable decline in the total return index.
B
Buy
4/7/2014Upgraded
Charles River Laboratories International, Inc. (CRL) was upgraded to B+ from B on 4/7/2014 due to an increase in the growth index, volatility index and valuation index.
Charles River Laboratories International, Inc. (CRL) was upgraded to B+ from B on 4/7/2014 due to an increase in the growth index, volatility index and valuation index.
B
Buy
3/21/2014Downgrade
Charles River Laboratories International, Inc. (CRL) was downgraded to B from B+ on 3/21/2014 due to a decline in the valuation index and total return index.
Charles River Laboratories International, Inc. (CRL) was downgraded to B from B+ on 3/21/2014 due to a decline in the valuation index and total return index.
B
Buy
2/28/2014Upgraded
Charles River Laboratories International, Inc. (CRL) was upgraded to B+ from B on 2/28/2014 due to a large increase in efficiency, growth and total return. Total capital increased 1.06% from $1.31B to $1.33B.
Charles River Laboratories International, Inc. (CRL) was upgraded to B+ from B on 2/28/2014 due to a large increase in efficiency, growth and total return. Total capital increased 1.06% from $1.31B to $1.33B.
NYSE
05/03/2024 4:00PM Eastern
Quotes delayed
